Robert E. Landry - Jan 23, 2024 Form 4 Insider Report for REGENERON PHARMACEUTICALS, INC. (REGN)

Role
EVP Finance CFO
Signature
/s/**Robert E. Landry
Stock symbol
REGN
Transactions as of
Jan 23, 2024
Transactions value $
-$464,512
Form type
4
Date filed
1/25/2024, 04:17 PM
Previous filing
Jan 18, 2024
Next filing
Feb 2, 2024

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction REGN Common Stock Options Exercise $417K +1.1K +4.79% $378.98 24.1K Jan 23, 2024 Direct
transaction REGN Common Stock Tax liability -$736K -776 -3.22% $948.50 23.3K Jan 23, 2024 Direct
transaction REGN Common Stock Options Exercise $189K +500 +2.15% $378.98 23.8K Jan 24, 2024 Direct
transaction REGN Common Stock Tax liability -$335K -352 -1.48% $951.26 23.5K Jan 24, 2024 Direct
holding REGN Common Stock 270 Jan 23, 2024 By 401(k) Plan

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction REGN Non-Qualified Stock Option (right to buy) Options Exercise $0 -1.1K -7.75% $0.00 13.1K Jan 23, 2024 Common Stock 1.1K $378.98 Direct F1
transaction REGN Non-Qualified Stock Option (right to buy) Options Exercise $0 -500 -3.82% $0.00 12.6K Jan 24, 2024 Common Stock 500 $378.98 Direct F1
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 The stock option award vests in four equal annual installments, commencing one year after the date of grant.